IN THIS ISSUE

Jaan Sidorov, MD, MHSA
The pros and cons of each weigh heavily, but ultimately, a melding may benefit patients and primary care physicians
Peer-Reviewed
Gary R. Bazalo, MS
Ashish V. Joshi, PhD
John Germak, MD
Payers' drug costs for human growth hormone are related to product waste that is related to the container in which the product is supplied
Legislation & Regulation
John Carroll
That seems to be the upshot of the debate over funding children's insurance and Medicare Advantage
Medication Management
Martin Sipkoff
Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share
Compensation Monitor
Tomorrow's Medicine
Thomas Morrow, MD
Otosclerosis has been traditionally managed with hearing aids and surgery, but a recent discovery may result in development of a biochemical treatment
Employer Update
Lola Butcher
Plans seem curiously unconcerned about technology that helps workers compare premiums, other features